Elizabeth Vroom’s Post

📢 We are pleased to announce the release of a comprehensive White Paper titled ‘𝗡𝗲𝘄𝗯𝗼𝗿𝗻 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗳𝗼𝗿 𝗗𝘂𝗰𝗵𝗲𝗻𝗻𝗲 𝗠𝘂𝘀𝗰𝘂𝗹𝗮𝗿 𝗗𝘆𝘀𝘁𝗿𝗼𝗽𝗵𝘆: 𝗧𝗵𝗲 𝗧𝗶𝗺𝗲 𝗶𝘀 𝗡𝗼𝘄’. The white paper provides a thorough analysis of the urgent need for NBS for DMD. It offers information and guidance for national patient organizations to advocate for starting a NBS program for DMD in their country or region. The paper was developed by a working group and reviewed by leading experts in the field. 👉 Access the white paper by clicking the link below. https://lnkd.in/eV7S-A8M #Duchenne #NewbornScreening #Healthcare #EarlyDiagnosis

Many sufferers of endometriosis know that it can be hard to be heard by medical professionals. This is a big factor in why it takes on average 9 years for women in the UK to be diagnosed with endometriosis, worsened by a systemic lack of disease understanding in endometriosis and other aspects of women’s health. This is why raising awareness is so important – to give patients a voice and, most importantly, for that voice to be heard. Fay Allen explores the progress being made in research, diagnosis and treatments for endometriosis from companies such as ENDODIAG, DotLab, Hera Biotech, Ziwig Biotech, Gynica Healthcare, and Gesynta Pharma AB. https://lnkd.in/gMs-DfhW #endometriosis #endometriosisawareness #womenshealth

Since we recently published our blog post regarding Innovation in Endometriosis care 📝, we thought it might be interesting to share this resource for founders! 💡 Read the full article here: https://lnkd.in/dMCn-87d #endometriosis #femtech #founder #innovation #healthtech

Did you know, 1 in 100 Americans live with #crohnsdisease or #ulcerativecolitis (#IBD)? Here is how Motilent is making a difference for those with #crohnsandcolitis : 🎯 Bringing #precision to #crohns : GIQuant, continues to provide quantified and objective scores to track treatment response in small bowel Crohn’s disease. Clinically used in both the US & UK redefining patient management. 🌟 Addressing Critical Needs: The James Lind Alliance IBD priority setting list identified perianal Crohn’s disease as a priority 5, we’re committed to advancing this area of medicine starting with vEUA. 🌍 Supporting research internationally: Entrolytics; Motilent’s cloud-based image viewing platform is now ready for clinical use in the US! It is already actively being used in over 300 projects, fostering international collaboration and providing researchers with the tooling they need to conduct pioneering research.  🤝 Supporting many of the biggest IBD Trials: With esteemed groups like International Bowel UltraSound (IBUS) Group, we're proud to support some of the most prominent IBD trials scheduled for 2024. These efforts represent just a glimpse of how we're dedicated to our mission of changing the way we see the gut to support individuals living with Crohn's and Colitis. #gastroenterology #abdominalradiology #medtech #precisionmedicine #IBDVisable #ibdawareness

What a heartfelt response, grateful for each voice message, email, text, post reply, repost and hug that I have received for this news. It means more than you can imagine. When we started embarking on this NIH SBIR journey, we faced a choice: play it safe with a Phase I or leap into a Direct-to-Phase II. Despite convention and recommendations to be more cautious as this would be our first submission ever to the NIH, internally and with our amazing advisors we had confidence in our readiness. You all know, my team and I have been all but conventional, through this journey we’ve had the privilege of working with talented people. Awesome people together, can achieve great things. We decided to go for the steeper Direct-to-Phase II path and we were supported by visionary, experienced clinical partners who dedicated a lot of time to support our efforts to submit an application so we can advance cardiovascular care for women. Fast forward many reviewers (>30) and a promising high impact score later ...we received the recommendation to re-submit (yeah I wasn’t expecting that either, but it happens...) feedback was great, so we iterated and resubmitted. Taking risks is never easy, and challenges always present just before the rewards. It worked! Receiving the Notice of Award for a Direct-to-Phase II to propel our progress is SO exciting. What we will learn from the clinical study will enable us to further generate novel digital biomarkers for women’s health to improve outcomes in her personal heart story.  Everyone that supports our work at Bloomer Tech adds strength to the future we envision. Your impact is immeasurable, and I am grateful beyond words. Every step of the way we have gained strength by surrounding ourselves with you. So again thank you for celebrating this news with us! 🌟 #Gratitude #CommunityPower

#Genetictesting in #reproductivemedicine is crucial for integrating #genomicinformation into individual-level care, resulting in improved outcomes. #obstetricsandgynecology #reproductivegenetics https://lnkd.in/dVjQWrUD

"Using online search activity for earlier detection of gynaecological malignancy" I'm excited by the potential of this paper, which is the first to link clinical diagnosis with online search activity. See https://lnkd.in/eqq8gtQ3 It builds on much earlier work we reported here: https://lnkd.in/eqYENKvf More research is needed but I hope this eventually has positive impact on people's health.

"EndoRISE is starting the chain to make a change with endometriosis; we're opening the dialogue and modeling one way forward, but our hope is the impact will reach to other neglected areas of health for people with uteruses like adenomyosis, uterine fibroids, heavy menstrual bleeding, etc. Showing positive impact by programs like EndoRISE could create a ripple effect if other states take actions too." - Elise Courtois, Ph.D., an endometriosis researcher at The Jackson Laboratory. This Connecticut-based program brings together researchers, healthcare providers, and advocates to enhance research, support, and education. Spearheaded by JAX, UConn Health, and supported by a $50,000 grant from EndoFound, EndoRISE aims to create a comprehensive biorepository for research collaboration. The launch event highlighted the importance of community support and advocacy in addressing this critical women's health issue.  Learn more: https://lnkd.in/gHdbi-Br

As research advances in #Sjögren’s disease, a new frontier in disease management is expected to emerge, driven by the use of biomarkers and targeted therapies. This #CME activity discusses differential diagnosis, multidisciplinary management, current and emerging treatment options, and strategies for improving quality of life for patients affected by Sjögren’s disease. This program is designed for #Rheumatologists, #pulmonologists, #neurologists, #nurse practitioners, #physicianassociates, NPs, and other health care providers who care for patients with Sjögren’s disease. https://lnkd.in/eD-NVPW5 #MedEd #MedicalEducation #FOAMed #PatientCare #RareDisease #Autoimmune

Join the conversation on ATTR-CM amyloidosis with Drs. Mazen Hanna and Marianna Fontana! This educational session focuses on the challenges of diagnosing ATTR-CM and reviews the latest advancements in treatment options. Perfect for primary care professionals looking to deepen their understanding of this cardiomyopathy. LINK: https://ow.ly/2EvN50Rhn6i #ATTRCM #Cardiomyopathy #PrimaryCare